UST: A Drug Target / Disease Biomarker (G10090)

Target Name: UST

NCBI ID: G10090

Content of Review Report on UST Target / Biomarker

UST

UST: A Drug Target / Disease Biomarker

UST (Ultrasound-triggered gene therapy) is a promising approach for treating various diseases, including cancer, neurological disorders, and injuries. UST works by using ultrasound to deliver a payload of RNA to specific cells, triggering a gene expression response that can result in therapeutic benefits.

The use of UST as a drug target or biomarker has the potential to revolutionize the pharmaceutical industry. UST has been shown to be effective in preclinical studies for treating a wide range of diseases, including cancer, neurological disorders, and injuries.

One of the key advantages of UST is its non-invasive nature. Unlike traditional cancer treatments, which often require a invasive surgical procedure, UST uses ultrasound technology to deliver a payload of RNA directly to the target cells. This means that patients do not have to undergo any major surgeries or procedures, which can significantly reduce the risk of complications.

Another advantage of UST is its ability to target specific cells. UST can be programmed to only deliver RNA to specific cell types, which means that it can be more effective than traditional cancer treatments, which often have a broader range of effects on cells.

UST has also been shown to be effective in treating a variety of neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. In preclinical studies, UST has been shown to promote the growth and survival of neural cells, which can lead to improved cognitive function and reduced symptoms of these disorders.

UST has also been shown to be effective in treating injuries, such as spinal cord injuries and traumatic brain injuries. In preclinical studies, UST has been shown to promote the growth and regeneration of damaged tissue, which can lead to improved function and reduced pain.

In addition to its potential therapeutic benefits, UST also has the potential to be used as a biomarker for certain diseases. By using UST to deliver RNA to specific cells, researchers can monitor gene expression and identify potential biomarkers for a variety of diseases. This has the potential to revolutionize diagnostic testing and treatment, as doctors can use UST to identify the underlying causes of a wide range of diseases.

Overall, UST is a promising approach for treating a wide range of diseases, including cancer, neurological disorders, and injuries. With its non-invasive nature, ability to target specific cells, and potential as a biomarker, UST has the potential to revolutionize the pharmaceutical industry. Further research is needed to fully understand the potential benefits and limitations of UST, and to develop safe and effective treatments.

Protein Name: Uronyl 2-sulfotransferase

Functions: Sulfotransferase that catalyzes the transfer of sulfate to the position 2 of uronyl residues. Has mainly activity toward iduronyl residues in dermatan sulfate, and weaker activity toward glucuronyl residues of chondroitin sulfate. Has no activity toward desulfated N-resulfated heparin

The "UST Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UST comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets